Prognostic factors in resectable cholangiocarcinoma patients: Carcinoembryonic antigen, lymph node, surgical margin and chemotherapy

Table 1 Baseline characteristics of 263 resectable cholangiocarcinoma patients n (%)

Age, yr
mean ± SD	59.0 ± 8.9
Range	35-80
Male	181 (69.6)
DM	19 (6.5)
BMI (mean ± SD), kg/m2
< 18.5	23 ± 8.7
18.5-22.9	127 ± 48.3
23-24.9	47 ± 17.9
25-29.9	48 ± 18.3
≥ 30	13 ± 4.9
Not available	5 ± 1.9
Clinical manifestation
Abdominal pain	164 (62.4)
Jaundice	54 (20.5)
Fever	6 (2.3)
Cholangitis	4 (1.5)
Weight loss	1 (0.4)
Asymptomatic	17 (6.5)
Hepatomegaly	153 (58.2)
Total bilirubin (mg/dL)
< 10	213 (81.0)
≥ 10	50 (19.0)
Cholesterol (mg/dL)
< 200	168 (63.9)
≥ 200	95 (36.1)
Albumin (g/dL)
< 3	42 (16.0)
≥ 3	220 (83.7)
ALT (U/L)
< 30	46 (17.5)
≥ 30	151 (82.5)
AST (U/L)
< 30	25 (9.5)
≥ 30	238 (90.5)
ALP (U/L)
< 100	82 (31.2)
≥ 100	180 (68.5)
CA 19-9 (U/mL)
< 35	108 (41.1)
≥ 35	148 (56.3)
CEA (ng/mL)
< 2.5	65 (24.7)
≥ 2.5	183 (69.6)
Receiving adjuvant chemotherapy
Yes	138 (52.5)
No	125 (47.5)

CA 19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; BMI: Body mass index; DM: Diabetes mellitus.